ETM
DGX icon

Euclidean Technologies Management’s Quest Diagnostics DGX Stock Holding History

Euclidean Technologies Management’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,370
Closed -$237K – 86
2021
Q4 		$237K Buy
+1,370
New +$208K 0.2% 69

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
Grantham, Mayo, Van Otterloo & Co (GMO)
Grantham, Mayo, Van Otterloo & Co (GMO) Boston, Massachusetts $39.1B AUM 28.69% 1-Year Est. Return

Euclidean Technologies Management's DGX Position: Q1 2022 in Review

Euclidean Technologies Management sold out of Quest Diagnostics (DGX) in Q1 2022, closing a stake of 1,370 shares — an estimated $237K sold.

Euclidean Technologies Management first reported a position in DGX in Q4 2021 and held it in 1 quarter. The position peaked at $237K in Q4 2021. 851 funds tracked by Wall St. Rank hold DGX as of Q1 2022.

  • Euclidean Technologies Management reported no remaining Quest Diagnostics position as of Q1 2022 after selling out during the quarter.
  • Euclidean Technologies Management sold 1,370 Quest Diagnostics shares in Q1 2022, an estimated $237K.
  • Euclidean Technologies Management first reported a position in Quest Diagnostics in Q4 2021 and held it in 1 quarter.
  • Euclidean Technologies Management's Quest Diagnostics position peaked at $237K in Q4 2021.
  • 851 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2022.

Based on Euclidean Technologies Management's 13F filing for Q1 2022, filed 28 Apr 2022.